Phase 2 N=80 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=63 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Primary: Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy — 79.8; 83.2; 66.7 Percent probability
Phase 3 N=194 A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia
Anemia
Primary: Percentage of Participants Maintaining Mean Hemoglobin Concentration Within +/- 1 g/dL of Their Reference Hb and Between 10.5 and 12.5 g/dL During Efficacy Evaluation…
N/A N=11 A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.
Seizure Disorders
Primary: Acceptability of FruitiVits — 8; 10; 6; 6 participants
Phase 4 N=79 Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department
Anxiety · Lacerations
Primary: Intention to Treat (ITT): Modified Yale Preoperative Anxiety Score (mYPAS) — 59.9201; 46.2871 units on a scale — p=0.026
Phase 1 N=42 A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) of Alectinib: Group 1 — 103; 270 nanograms per milliliter (ng/mL)
Phase 4 N=101 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
Breast Neoplasms · Breast Cancer
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE) — 101; 20 Participants
N/A N=121 MRI of Infrapatellar Fat Pad in Osteoarthritis
Osteoarthritis
Primary: Infrapatellar Fat Pad Volume in MRI — 25154.96; 29202.39 mm^3
N/A N=28 Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial
Temporomandibular Joint Dysfunction Syndrome
Primary: Self Report of Pain — -.86; -2.0; -1.4; -1.3 Scores on pain intensity scale — p=0.17
Phase 2 N=63 Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Staphylococcus Aureus Infection
Primary: Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method. — 3; 1; 4 participants — p=0.792
Phase 3 N=394 A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Psoriasis
Primary: Percentage of Participants With Success According to the Investigator Global Assessment (IGA) — 19.0; 2.3 percentage of patients — p=<0.001
Early Phase 1 N=15 n-Acetylcysteine and Cocaine
Cocaine Abuse · Cocaine Dependence
Primary: Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 1.0; 0.1; 3.4; 3.9 Number of Cocaine Choices
N/A N=90 Acceptance-based Group Intervention for Binge Eating
Binge-Eating Disorder
Primary: Change From Baseline in Binge Eating Scale (BES) at 4 Weeks, 3 Months and 6 Months — 17.38; 15.45; 10.52; 13.52 units on a scale
N/A N=44 LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Ulcer Healing Within 20 Weeks — 23; 23 participants
Phase 4 N=36 Ictal and Interictal Inflammatory Markers in Migraine
Migraine
Primary: Change in the Total Serum Adiponectin (T-ADP) — -0.96; 0.25; -0.97; 0.29 ug/mL